Table Info

Table 2.

BW, serum glucose and lipid profile of NP-treated ApoE-null mice

Treatment	Sex (n)	Initial BW (g)	Final BW (g)	Glucose (mg/dL)	Cholesterol (mg/dL)	Triglycerides (mg/dL)	HDL (mg/dL)
Vehicle	F (10)	29.1 ± 3.4	31.0 ± 3.3	143.2 ± 18.0	434.4 ± 65.4	152.8 ± 72.8	2.7 ± 2.6
	M (10)	31.5 ± 2.3	31.5 ± 4.6	149.2 ± 41.9	448.9 ± 95.2	182.0 ± 78.5	8.4 ± 3.3
	Total (20)	30.3 ± 2.9	31.3 ± 3.9	146.2 ± 29.9	441.6 ± 80.3	167.4 ± 75.7	5.6 ± 4.1
HSANP	F (10)	28.4 ± 1.9	31.2 ± 3.6	143.9 ± 22.3	506.3 ± 139.3	169.1 ± 45.6	15.5 ± 9.2
	M (10)	33.3 ± 1.6	34.5 ± 2.0	137.9 ± 9.5	446.8 ± 96.1	163.1 ± 41.2	15.4 ± 1.2
	Total (20)	30.8 ± 1.8	32.9 ± 2.8	140.9 ± 15.9	476.5 ± 11.7	166.1 ± 43.4	15.4 ± 12.3
HSANP-FLAGPP1	F (5)	31.1 ± 1.7	36.3 ± 30.7	175.0 ± 37.4	539.3 ± 224.2	250.1 ± 216.5	19.7 ± 6.3
	M (5)	29.5 ± 1.6	30.7 ± 2.4	127.0 ± 19.4	394.8 ± 107.2	125.6 ± 56.2	14.2 ± 8.1
	Total (10)	30.3 ± 1.6	33.5 ± 2.9	151.0 ± 28.3	467.1 ± 165.7	187.8 ± 136.3	16.9 ± 11.6 (P = 0.028)
S-HSANP-FLAGPP1	F (10)	27.0 ± 3.9	29.0 ± 3.7	148.7 ± 20.8	464.1 ± 108.3	147. ± 61.2	15.4 ± 11.8
	M (10)	32.3 ± 3.5	31.7 ± 4.2	144.3 ± 28.1	489.1 ± 215.9	161.6 ± 46.1	16.3 ± 2.1
	Total (20)	29.6 ± 3.7	30.3 ± 4.0	146.5 ± 24.5	154.7 ± 53.6	476.6 ± 162.1	15.9 ± 13.8
SGI-HSA	F (5)	29.6 ± 2.9	33.8 ± 2.2	177.0 ± 38.4	555.4 ± 300.9	261.2 ± 197.2	22.7 ± 13.5
	M (5)	28.2 ± 2.1	31.6 ± 2.5	131.8 ± 23.0	311.7 ± 239.3	111.8 ± 91.6	12.0 ± 8.6
	Total (10)	28.9 ± 2.5	32.7 ± 2.3	154.4 ± 30.7	433.6 ± 270.1	186.5 ± 144.4	17.3 ± 15.4 (P = 0.020)

F: female; M: male. Data are mean ± SD. Significance refers to comparison with vehicle control. Only significant P values are shown. ANOVA, Bonferroni post hoc test

Supplementary materials

The supplementary material for this article is available at: https://www.explorationpub.com/uploads/Article/file/101221_sup_1.pdf.

Declarations

Acknowledgments

We thank the personnel of Cedars-Sinai Medical Center Microscopy Core, Los Angeles, CA, USA; Dr. Jiani Zhu, Postdoctoral Scientist, Medicine Department, Cedars Sinai Medical Center, Los Angeles, CA, USA; and the personnel of the Flow Cytometry Core, XXI Century National Medical Center, Mexico City, Mexico, for their generous assistance. This article is in memory of Dr. Jorge A. Martínez García, excellent colleague and pathologist, generous collaborator who has given assistance and advice during the early phase of this study.

Author contributions

ACMS: Investigation, Writing—original draft. AMG, DCC, and GdCRM: Investigation. RCJ and EKK: Supervision, Validation. LSS: Investigation, Supervision, Validation. DK and DRR: Investigation, Formal analysis. AMA: Validation, Supervision. GL: Supervision, Validation, Writing—review & editing. SZ: Conceptualization, Supervision, Writing—review & editing.

Conflicts of interest

SZ filed a patent application regarding the SGI-1027-loaded, PP1-functionalized HSA NP described here. The patent (patent number: MX/a/2019/015004) is of no financial interest to the subject matter and material of the manuscript. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Ethical approval

The laboratory animal protocol was approved by the committee for ethics in research of the University of Guanajuato (approval no. CIBIUG-P10-2017) and performed in agreement with the official Mexican guideline for the use of laboratory animals NOM-062-ZOO-1999.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

The data analyzed in this study was obtained from our own experimental work. Requests for access to these datasets should be directed to Silvio Zaina, szaina@ugto.mx.

Funding

Work was supported by the Mexican Council for Humanities, Science and Technology (CONAHCyT) Proyectos de desarrollo científico para atender problemas nacionales grant no. [584] to SZ; and by the University of Guanajuato Convocatoria Institucional de Investigación Científica grant no. [045/2019] to SZ. CONAHCyT fellowships supported DCC (Postdoctoral), ACMS (PhD), AMG (MSc) and GdCRM (“Ayudante a SNI3/Emérito”). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Susser LI, Rayner KJ. Through the layers: how macrophages drive atherosclerosis across the vessel wall. J Clin Invest. 2022;132:e157011. [DOI] [PubMed] [PMC]

Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442. [DOI] [PubMed] [PMC]

Song P, Fang Z, Wang H, Cai Y, Rahimi K, Zhu Y, et al. Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: a systematic review, meta-analysis, and modelling study. Lancet Glob Health. 2020;8:e721–9. [DOI] [PubMed]

Herrington W, Lacey B, Sherliker P, Armitage J, Lewington S. Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. Circ Res. 2016;118:535–46. [DOI] [PubMed]

Matsuura Y, Kanter JE, Bornfeldt KE. Highlighting residual atherosclerotic cardiovascular disease risk. Arterioscler Thromb Vasc Biol. 2019;39:e1–9. [DOI] [PubMed] [PMC]

Arnold N, Lechner K, Waldeyer C, Shapiro MD, Koenig W. Inflammation and cardiovascular disease: the future. Eur Cardiol. 2021;16:e20. [DOI] [PubMed] [PMC]

Stadler MB, Murr R, Burger L, Ivanek R, Lienert F, Schöler A, et al. DNA-binding factors shape the mouse methylome at distal regulatory regions. Nature. 2011;480:490–5. Erratum in: Nature. 2012;484:550. [DOI] [PubMed]

Bertozzi TM, Takahashi N, Hanin G, Kazachenka A, Ferguson-Smith AC. A spontaneous genetically induced epiallele at a retrotransposon shapes host genome function. Elife. 2021;10:e65233. [DOI] [PubMed] [PMC]

Seisenberger S, Peat JR, Hore TA, Santos F, Dean W, Reik W. Reprogramming DNA methylation in the mammalian life cycle: building and breaking epigenetic barriers. Philos Trans R Soc Lond B Biol Sci. 2013;368:20110330. [DOI] [PubMed] [PMC]

10.

Greenberg MVC, Bourc’his D. The diverse roles of DNA methylation in mammalian development and disease. Nat Rev Mol Cell Biol. 2019;20:590–607. [DOI] [PubMed]

11.

Lund G, Andersson L, Lauria M, Lindholm M, Fraga MF, Villar-Garea A, et al. DNA methylation polymorphisms precede any histological sign of atherosclerosis in mice lacking apolipoprotein E*. J Biol Chem. 2004;279:29147–54. [DOI] [PubMed]

12.

Aavik E, Lumivuori H, Leppänen O, Wirth T, Häkkinen SK, Bräsen JH, et al. Global DNA methylation analysis of human atherosclerotic plaques reveals extensive genomic hypomethylation and reactivation at imprinted locus 14q32 involving induction of a miRNA cluster. Eur Heart J. 2015;36:993–1000. [DOI] [PubMed]

13.

Castillo-Díaz SA, Garay-Sevilla ME, Hernández-González MA, Solís-Martínez MO, Zaina S. Extensive demethylation of normally hypermethylated CpG islands occurs in human atherosclerotic arteries. Int J Mol Med. 2010;26:691–700. [DOI] [PubMed]

14.

Zaina S, Heyn H, Carmona FJ, Varol N, Sayols S, Condom E, et al. DNA methylation map of human atherosclerosis. Circ Cardiovasc Genet. 2014;7:692–700. [DOI] [PubMed]

15.

Valencia-Morales Mdel P, Zaina S, Heyn H, Carmona FJ, Varol N, Sayols S, et al. The DNA methylation drift of the atherosclerotic aorta increases with lesion progression. BMC Med Genomics. 2015;8:7. [DOI] [PubMed] [PMC]

16.

Jiang D, Sun M, You L, Lu K, Gao L, Hu C, et al. DNA methylation and hydroxymethylation are associated with the degree of coronary atherosclerosis in elderly patients with coronary heart disease. Life Sci. 2019;224:241–8. [DOI] [PubMed]

17.

de la Rocha C, Zaina S, Lund G. Is any cardiovascular disease-specific DNA methylation biomarker within reach? Curr Atheroscler Rep. 2020;22:62. [DOI] [PubMed]

18.

Rangel-Salazar R, Wickström-Lindholm M, Aguilar-Salinas CA, Alvarado-Caudillo Y, Døssing KB, Esteller M, et al. Human native lipoprotein-induced de novo DNA methylation is associated with repression of inflammatory genes in THP-1 macrophages. BMC Genomics. 2011;12:582. [DOI] [PubMed] [PMC]

19.

Silva-Martínez GA, Rodríguez-Ríos D, Alvarado-Caudillo Y, Vaquero A, Esteller M, Carmona FJ, et al. Arachidonic and oleic acid exert distinct effects on the DNA methylome. Epigenetics. 2016;11:321–34. [DOI] [PubMed] [PMC]

20.

Hall E, Volkov P, Dayeh T, Bacos K, Rönn T, Nitert MD, et al. Effects of palmitate on genome-wide mRNA expression and DNA methylation patterns in human pancreatic islets. BMC Med. 2014;12:103. [DOI] [PubMed] [PMC]

21.

Koseler A, Ma F, Kilic ID, Morselli M, Kilic O, Pellegrini M. Genome-wide DNA methylation profiling of blood from monozygotic twins discordant for myocardial infarction. In Vivo. 2020;34:361–7. [DOI] [PubMed] [PMC]

22.

Jiang YZ, Jiménez JM, Ou K, McCormick ME, Zhang LD, Davies PF. Hemodynamic disturbed flow induces differential DNA methylation of endothelial kruppel-like factor 4 promoter in vitro and in vivo. Circ Res. 2014;115:32–43. [DOI] [PubMed] [PMC]

23.

Li B, Zang G, Zhong W, Chen R, Zhang Y, Yang P, et al. Activation of CD137 signaling promotes neointimal formation by attenuating TET2 and transferrring from endothelial cell-derived exosomes to vascular smooth muscle cells. Biomed Pharmacother. 2020;121:109593. [DOI] [PubMed]

24.

Zhaolin Z, Jiaojiao C, Peng W, Yami L, Tingting Z, Jun T, et al. OxLDL induces vascular endothelial cell pyroptosis through miR-125a-5p/TET2 pathway. J Cell Physiol. 2019;234:7475–91. [DOI] [PubMed]

25.

Yu J, Qiu Y, Yang J, Bian S, Chen G, Deng M, et al. DNMT1-PPARγ pathway in macrophages regulates chronic inflammation and atherosclerosis development in mice. Sci Rep. 2016;6:30053. [DOI] [PubMed] [PMC]

26.

Zhuang J, Luan P, Li H, Wang K, Zhang P, Xu Y, et al. The Yin–Yang Dynamics of DNA methylation is the key regulator for smooth muscle cell phenotype switch and vascular remodeling. Arterioscler Thromb Vasc Biol. 2017;37:84–97. [DOI] [PubMed]

27.

Dunn J, Qiu H, Kim S, Jjingo D, Hoffman R, Kim CW, et al. Flow-dependent epigenetic DNA methylation regulates endothelial gene expression and atherosclerosis. J Clin Invest. 2014;124:3187–99. [DOI] [PubMed] [PMC]

28.

Cao Q, Wang X, Jia L, Mondal AK, Diallo A, Hawkins GA, et al. Inhibiting DNA methylation by 5-Aza-2’-deoxycytidine ameliorates atherosclerosis through suppressing macrophage inflammation. Endocrinology. 2014;155:4925–38. [DOI] [PubMed] [PMC]

29.

Strand KA, Lu S, Mutryn MF, Li L, Zhou Q, Enyart BT, et al. High throughput screen identifies the DNMT1 (DNA methyltransferase-1) inhibitor, 5-azacytidine, as a potent inducer of PTEN (phosphatase and tensin homolog): central role for PTEN in 5-azacytidine protection against pathological vascular remodeling. Arterioscler Thromb Vasc Biol. 2020;40:1854–69. [DOI] [PubMed] [PMC]

30.

Peng J, Yang Q, Li AF, Li RQ, Wang Z, Liu LS, et al. Tet methylcytosine dioxygenase 2 inhibits atherosclerosis via upregulation of autophagy in ApoE^−/− mice. Oncotarget. 2016;7:76423–36. [DOI] [PubMed] [PMC]

31.

Hassanin I, Elzoghby A. Albumin-based nanoparticles: a promising strategy to overcome cancer drug resistance. Cancer Drug Resist. 2020;3:930–46. [DOI] [PubMed] [PMC]

32.

Ahmed M, Baumgartner R, Aldi S, Dusart P, Hedin U, Gustafsson B, et al. Human serum albumin-based probes for molecular targeting of macrophage scavenger receptors. Int J Nanomedicine. 2019;14:3723–41. [DOI] [PubMed] [PMC]

33.

Li LH, Olin EJ, Buskirk HH, Reineke LM. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res. 1970;30:2760–9. [PubMed]

34.

Veselý J, Cihák A. Incorporation of a potent antileukemic agent, 5-aza-2’-deoxycytidine, into DNA of cells from leukemic mice. Cancer Res. 1977;37:3684–9. [PubMed]

35.

Segers FM, Yu H, Molenaar TJ, Prince P, Tanaka T, van Berkel TJ, et al. Design and validation of a specific scavenger receptor class AI binding peptide for targeting the inflammatory atherosclerotic plaque. Arterioscler Thromb Vasc Biol. 2012;32:971–8. [DOI] [PubMed]

36.

Sánchez-Arreguin A, Carriles R, Ochoa-Alejo N, López MG, Sánchez-Segura L. Generation of BSA-capsaicin nanoparticles and their hormesis effect on the Rhodotorula mucilaginosa yeast. Molecules. 2019;24:2800. [DOI] [PubMed] [PMC]

37.

Ulbrich K, Knobloch T, Kreuter J. Targeting the insulin receptor: nanoparticles for drug delivery across the blood–brain barrier (BBB). J Drug Target. 2011;19:125–32. [DOI] [PubMed]

38.

Chilom C, Baranǧ G, Gǎzdaru D, Popescu A. Characterisation by fluorescence of human and bovine serum albumins in interaction with eosin Y. J Optoelectron Adv Mater. 2013;15:311–6.

39.

Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992;258:468–71. [DOI]

40.

Brånén L, Pettersson L, Lindholm M, Zaina S. A procedure for obtaining whole mount mouse aortas that allows atherosclerotic lesions to be quantified. Histochem J. 2001;33:227–9. [DOI]

41.

Brenu EW, van Driel ML, Staines DR, Ashton KJ, Hardcastle SL, Keane J, et al. Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med. 2012;10:88. [DOI] [PubMed] [PMC]

42.

Liu D, Li C, Chen Y, Burnett C, Liu XY, Downs S, et al. Nuclear import of proinflammatory transcription factors is required for massive liver apoptosis induced by bacterial lipopolysaccharide*. J Biol Chem. 2004;279:48434–42. [DOI] [PubMed]

43.

Bais AG, Beckmann I, Ewing PC, Eijkemans MJ, Meijer CJ, Snijders PJ, et al. Cytokine release in HR-HPV(+) women without and with cervical dysplasia (CIN II and III) or carcinoma, compared with HR-HPV(−) controls. Mediators Inflamm. 2007;2007:24147. [DOI] [PubMed] [PMC]

44.

Zhang L, Ignatowski TA, Spengler RN, Noble B, Stinson MW. Streptococcal histone induces murine macrophages to produce interleukin-1 and tumor necrosis factor alpha. Infect Immun. 1999;67:6473–7. [DOI] [PubMed] [PMC]

45.

Cohen-Sela E, Dangoor D, Epstein H, Gati I, Danenberg HD, Golomb G, et al. Nanospheres of a bisphosphonate attenuate intimal hyperplasia. J Nanosci Nanotechnol. 2006;6:3226–34. [DOI] [PubMed]

46.

D’Uscio LV, Smith LA, Katusic ZS. Hypercholesterolemia impairs endothelium-dependent relaxations in common carotid arteries of apolipoprotein E-deficient mice. Stroke. 2001;32:2658–64. [DOI] [PubMed]

47.

Yoo J, Choi S, Medina-Franco JL. Molecular modeling studies of the novel inhibitors of DNA methyltransferases SGI-1027 and CBC12: implications for the mechanism of inhibition of DNMTs. PLoS One. 2013;8:e62152. [DOI] [PubMed] [PMC]

48.

Sun N, Zhang J, Zhang C, Zhao B, Jiao A. DNMTs inhibitor SGI‑1027 induces apoptosis in Huh7 human hepatocellular carcinoma cells. Oncol Lett. 2018;16:5799–806. [DOI] [PubMed] [PMC]

49.

Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20:101–24. [DOI] [PubMed] [PMC]

50.

Cooley M, Sarode A, Hoore M, Fedosov DA, Mitragotri S, Sen Gupta A. Influence of particle size and shape on their margination and wall-adhesion: implications in drug delivery vehicle design across nano-to-micro scale†. Nanoscale. 2018;10:15350–64. [DOI] [PubMed] [PMC]

51.

Petryk N, Bultmann S, Bartke T, Defossez PA. Staying true to yourself: mechanisms of DNA methylation maintenance in mammals. Nucleic Acids Res. 2021;49:3020–32. [DOI] [PubMed] [PMC]

52.

Poirier S, Samami S, Mamarbachi M, Demers A, Chang TY, Vance DE, et al. The epigenetic drug 5-azacytidine interferes with cholesterol and lipid metabolism*. J Biol Chem. 2014;289:18736–51. [DOI] [PubMed] [PMC]

53.

Zimmerman MA, Reznikov LL, Raeburn CD, Selzman CH. Interleukin-10 attenuates the response to vascular injury1,2. J Surg Res. 2004;121:206–13. [DOI] [PubMed]

54.

Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis^*. Annu Rev Immunol. 2009;27:165–97. [DOI] [PubMed] [PMC]

55.

Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF, et al. Protective role of interleukin-10 in atherosclerosis. Circ Res. 1999;85:e17–24. [DOI] [PubMed]

56.

Stöger JL, Goossens P, de Winther MP. Macrophage heterogeneity: relevance and functional implications in atherosclerosis. Curr Vasc Pharmacol. 2010;8:233–48. [DOI] [PubMed]

57.

Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6:508–19. [DOI] [PubMed]

58.

Hermansson A, Ketelhuth DF, Strodthoff D, Wurm M, Hansson EM, Nicoletti A, et al. Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. J Exp Med. 2010;207:1081–93. [DOI] [PubMed] [PMC]

59.

Gomes FLT, Maranhão RC, Tavares ER, Carvalho PO, Higuchi ML, Mattos FR, et al. Regression of atherosclerotic plaques of cholesterol-fed rabbits by combined chemotherapy with paclitaxel and methotrexate carried in lipid core nanoparticles. J Cardiovasc Pharmacol Ther. 2018;23:561–9. [DOI] [PubMed]

60.

Manolis AA, Manolis TA, Melita H, Mikhailidis DP, Manolis AS. Low serum albumin: a neglected predictor in patients with cardiovascular disease. Eur J Intern Med. 2022;102:24–39. [DOI] [PubMed]

61.

Zhong X, Jiao H, Zhao D, Teng J. Association between serum albumin levels and paroxysmal atrial fibrillation by gender in a Chinese population: a case–control study. BMC Cardiovasc Disord. 2022;22:387. [DOI] [PubMed] [PMC]

62.

Gillum RF. The association between serum albumin and HDL and total cholesterol. J Natl Med Assoc. 1993;85:290–2. [PubMed] [PMC]

63.

Mao Y, Ren J, Yang L. Advances of nanomedicine in treatment of atherosclerosis and thrombosis. Environ Res. 2023;238:116637. [DOI] [PubMed]